1. Ireland Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Malin Corporation PLC

Malin Corporation PLC

EEURONEXT:MLC
6.80
EUR
-0.10
(-1.45%)
163.15MMarket Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
0.83
1.07
1
0.83
0.76
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-1.63
-2.12
-2.36
-1.01
-0.12
1.91
0.85
0.38
- -
- -
- -
Free Cash Flow per Basic Share
-0.65
-0.65
-0.75
-0.4
-0.15
-0.11
-0.14
-0.21
-0.14
-0.07
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
8.22
6.67
4.54
3.28
3.44
5.68
5.87
8.21
5.77
10.18
10.18
Tangible Book Value per Share
7.01
5.32
3.68
2.53
2.75
5.09
5.87
8.21
5.77
10.18
10.18
Basic Weighted Avg Shares
28
39
42
46
46
46
45
34
22
19
19
Sales/Revenue/Turnover
23
42
42
38
35
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-117.9
-133.49
-108.11
-61.32
-40.11
- -
- -
- -
- -
- -
- -
Depreciation Expense
3
5
5
5
5
5
4
- -
- -
- -
- -
Net Income, GAAP
-45
-83
-99
-46
-5
88
38
13
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
3.91
- -
- -
- -
- -
- -
Profit Margin (%)
-196.07
-198.34
-235.8
-121.84
-15.47
- -
- -
- -
- -
- -
- -
Working Capital
106
60
35
35
36
22
35
175
35
62
62
LT Debt
28
63
58
55
56
42
- -
- -
- -
- -
- -
Total Equity
365
308
221
170
179
290
219
283
110
193
193
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-1.83
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
30.35
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-26.29
-40.06
-25.18
-3.28
39.09
15.16
5.14
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
19
19
19
Market Capitalization
85
112
163

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
36
36
63
Cash, Cash Equivalents & STI
36
36
62
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
16.38%
76.44%
Free Cash Flow
- -
-20.66%
-59.37%
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
- -
2023
- -
- -
- -
2024
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
0.38
2023
- -
- -
- -
2024
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
- -
2023
- -
- -
- -
2024
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Fiona Dunlevy
Full Time Employees
2
Sector
Health technology
Industry
Biotechnology
Address
The Lennox Building Dublin DU Ireland D02 FK02
IPO Date
Mar 25, 2015
Website
malibplc.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Malin Corporation plc is a Dublin-headquartered global life sciences investment company founded in 2014. It focuses on investing in and supporting innovative life sciences companies engaged in oncology, immunology, genetic diseases, and diverse therapeutic areas. Its core portfolio includes investments in clinical, discovery, and commercial stage companies such as Poseida Therapeutics, Viamet Pharmaceuticals, Xenex Disinfection Services, WaveBreak Therapeutics, KNOW Bio, and Artizan Biosciences. These companies develop products and technologies including chimeric antigen receptor T-cell (CAR-T) therapies, medicines targeting protein-misfolding diseases, and non-mercury disinfection devices. Malin's operations span primarily Ireland, the United States, and broader international markets. Recent major changes include the completion of the sale of its entire 12% interest in Poseida Therapeutics to Roche in January 2025, generating upfront proceeds of approximately $106.5 million plus contingent milestone payments of up to $47.3 million. In July 2024, Malin divested its entire interest in CG Oncology for around €28.5 million, achieving a 175% gain on invested capital. These transactions align with Malin's strategy to maximize investee value and return capital to shareholders, exemplified by a tender offer to return up to €150 million in capital launched in early 2025. Additionally, Malin increased its cash reserves significantly in 2024 through these divestments and milestone payments. The company remains committed to deploying capital in high-potential life sciences ventures and managing its portfolio to optimize shareholder returns.